Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas

Journal for Immunotherapy of Cancer
Won Jin HoHyunseok Kang

Abstract

Low absolute lymphocyte count (ALC) has previously been established as a marker of poor prognosis in multiple cancer types. There is growing evidence that ALC may also be associated with response to immunotherapy. This study explores whether response to PD1 inhibitors in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is associated with pretreatment ALC. Thirty-four R/M HNSCC patients who received either nivolumab or pembrolizumab between January 2014 and May 2018 at Johns Hopkins were identified retrospectively. Pretreatment blood counts in patients with and without clinical benefit from PD1 inhibitors were compared. Time-to-progression analyses were performed by dichotomizing the study cohort with the threshold of ALC 600 cells/μl, which is approximately 1.5 standard deviations away from treatment-naïve baseline mean. Patients with lower ALC appeared to have significantly less clinical benefit from anti-PD1 therapy. Those patients with pretreatment ALC < 600 cells/μl also had shorter PFS than patients with pretreatment ALC ≥ 600 cells/μl (median PFS 60 days vs. 141 days, p < 0.05). These results were consistent with multivariate proportional hazards analyses demonstrating significant association ...Continue Reading

References

Jun 25, 2009·Cancer Research·Isabelle Ray-CoquardUNKNOWN European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Mar 23, 2012·Nature Reviews. Cancer·Drew M Pardoll
Feb 26, 2013·Cancer Investigation·Jian L CampianStuart A Grossman
May 31, 2014·Journal of the National Cancer Institute·Arnoud J TempletonEitan Amir
Jul 8, 2014·The Medical Journal of Australia·Marliese AlexanderDamien Kee
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P F FerrucciC Martinoli
Jan 29, 2016·Journal of Immunology Research·Eileen Uribe-Querol, Carlos Rosales
Nov 1, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin WeideJedd D Wolchok
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison
Mar 14, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Stephen J BagleyCorey J Langer
Mar 23, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joshua BaumlRobert Haddad
Jun 14, 2017·Cancer Cell·Gabriel Abril-Rodriguez, Antoni Ribas
Jul 12, 2017·Critical Reviews in Oncology/hematology·Saman Maleki VarekiIgnacio Duran
Oct 24, 2017·Annals of Translational Medicine·Khinh Ranh VoongBenjamin Levy
May 13, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·A Dimitrios ColevasSusan D Darlow

❮ Previous
Next ❯

Citations

Apr 12, 2020·International Journal of Clinical Oncology·C SuzukiH Minami
Apr 22, 2020·Oral Diseases·Giuseppe FanettiBarbara Alicja Jereczek-Fossa
Sep 17, 2020·ESMO Open·Nikki Burdett, Jayesh Desai
Nov 28, 2018·Cancers·Daisuke NishikawaNobuhiro Hanai
Aug 17, 2019·Frontiers in Medicine·Yumi KambayashiSetsuya Aiba
Apr 15, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·K HolubA Biete
Mar 30, 2019·Journal for Immunotherapy of Cancer·Christine Ménétrier-CauxChristophe Caux
Apr 26, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Flor MendezMaria G Castro
Jan 23, 2021·Critical Reviews in Oncology/hematology·Michael I Koukourakis, Alexandra Giatromanolaki
Aug 18, 2020·International Journal of Radiation Oncology, Biology, Physics·Roshal R PatelJames W Welsh
Feb 22, 2021·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Cole FriedesJosephine L Feliciano
May 27, 2021·Therapeutic Advances in Neurological Disorders·Nora MöhnKurt-Wolfram Sühs
Jul 25, 2021·Journal for Immunotherapy of Cancer·Julien FagetNathalie Bonnefoy
May 27, 2020·Bulletin du cancer·Mathieu CesaireJuliette Thariat

❮ Previous
Next ❯

Software Mentioned

JMP Pro

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.